A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
JP Morgan approaches.
Four months after yielding first-in-human data INCA33890 enters phase 3.
